Formulation Kills More Drugs Than Biology—We're Solving the Wrong Problem

Here's what pharma doesn't want you to know: 40% of new chemical entities fail not because they don't work, but because we can't get them into the body effectively. We're obsessing over target selection while ignoring the delivery problem.

The data is stark. Of drugs that fail in clinical trials, nearly half fail due to ADME issues—absorption, distribution, metabolism, excretion. The molecule works in the lab. It works in cell culture. It even works in animals. But put it in a human and it never reaches the target tissue.

Notice what's missing from most biotech pitches: serious formulation strategy. Everyone talks about their brilliant target, their novel mechanism, their preclinical efficacy. Nobody talks about bioavailability, solubility, stability, or half-life. The biology gets the glory; the chemistry does the work.

The FDA's own data reveals the pattern. Lipophilic drugs can't dissolve. Hydrophilic drugs can't cross membranes. Large molecules can't reach intracellular targets. Unstable molecules degrade before they reach the site of action. Same story, different molecule.

Here's the translation insight: the real innovation opportunity isn't new targets—it's better delivery systems for existing targets. The graveyard of failed drugs represents billions in wasted R&D on molecules that could work if we could just get them where they need to go.

Current development paradigm: find target, design molecule, worry about delivery later. Smarter paradigm: start with delivery constraints, then design molecules that work within those constraints. Medicinal chemistry follows formulation requirements, not the other way around.

Consider the success stories. mRNA vaccines didn't work until lipid nanoparticles solved the delivery problem. Antisense oligonucleotides required chemical modifications and targeting ligands. The biology was known for decades—the delivery breakthrough made them viable.

The DeSci advantage: BioDAOs can prioritize formulation science from day one. Pool expertise in drug delivery, share formulation failures and successes, coordinate around platform delivery technologies. Instead of each group solving delivery independently, create shared infrastructure for getting molecules where they need to go.

The investment opportunity is hiding in plain sight. While everyone chases novel biology, the real returns are in solving delivery problems for existing targets. Same therapeutic outcome, higher probability of success.

Testable prediction: By 2027, a BioDAO focused on formulation-first drug development will demonstrate higher clinical success rates than traditional target-first approaches, with >60% of candidates reaching primary endpoints vs industry average of 30%.

We're not discovering new biology. We're delivering known biology better. The difference is everything.